key: cord-0866490-s6ti599i
authors: Yee, Sook Wah; Vora, Bianca; Oskotsky, Tomiko; Zou, Ling; Jakobsen, Sebastian; Enogieru, Osatohanmwen J.; Koleske, Megan L.; Kosti, Idit; Rödin, Mattias; Sirota, Marina; Giacomini, Kathleen M.
title: Drugs in COVID‐19 Clinical Trials: Predicting Transporter‐Mediated Drug‐Drug Interactions Using In Vitro Assays and Real‐World Data
date: 2021-05-03
journal: Clin Pharmacol Ther
DOI: 10.1002/cpt.2236
sha: de5f1051596369fd7a8f40624797a1c312d7fd19
doc_id: 866490
cord_uid: s6ti599i

Numerous drugs are currently under accelerated clinical investigation for the treatment of coronavirus disease 2019 (COVID‐19); however, well‐established safety and efficacy data for these drugs are limited. The goal of this study was to predict the potential of 25 small molecule drugs in clinical trials for COVID‐19 to cause clinically relevant drug‐drug interactions (DDIs), which could lead to potential adverse drug reactions (ADRs) with the use of concomitant medications. We focused on 11 transporters, which are targets for DDIs. In vitro potency studies in membrane vesicles or HEK293 cells expressing the transporters coupled with DDI risk assessment methods revealed that 20 of the 25 drugs met the criteria from regulatory authorities to trigger consideration of a DDI clinical trial. Analyses of real‐world data from electronic health records, including a database representing nearly 120,000 patients with COVID‐19, were consistent with several of the drugs causing transporter‐mediated DDIs (e.g., sildenafil, chloroquine, and hydroxychloroquine). This study suggests that patients with COVID‐19, who are often older and on various concomitant medications, should be carefully monitored for ADRs. Future clinical studies are needed to determine whether the drugs that are predicted to inhibit transporters at clinically relevant concentrations, actually result in DDIs.

 As the coronavirus disease 2019 (COVID-19) pandemic continues to plague the world, approved drugs and new molecular entities are being evaluated at an unprecedented pace. Patients diagnosed with COVID-19 may be increasingly vulnerable to incur significant drug-drug interactions (DDIs), especially older patients who are more susceptible to COVID-19-related morbidities and in whom polypharmacy is most common. Although there have been a few studies of DDIs, caused by individual drugs in clinical trials for COVID- 19 , there has been no largescale study evaluating the potential of many drugs in clinical trials for COVID-19 to cause a clinical DDI.

 In this study, we conducted extensive in vitro experiments aimed at predicting the potential for 25 small molecule drugs in clinical trials for COVID-19 to cause transporter-mediated DDIs and used real-world data to provide preliminary support of our in vitro findings.

Adverse drug reactions are often a result of drug-drug interactions (DDIs), especially in patients for whom polypharmacy is common. It is estimated that the prevalence of clinically relevant DDIs is about 50% in those taking 5, and almost 100% in those taking 10 medications. 1, 2 DDIs can influence drug efficacy and toxicity by affecting pharmacokinetics through the inhibition or induction of drug metabolizing enzymes and transporters in the intestines, liver, and kidneys. 3, 4 As the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to plague the world, approved drugs and new molecular entities are being evaluated at an unprecedented pace. Patients diagnosed with COVID-19 may be increasingly vulnerable to incur a significant DDI, especially older patients who are more susceptible to comorbidities associated with COVID-19 and in whom pre-existing multimorbidity and polypharmacy 5 are most common.

Membrane transporters are important targets for DDIs as they play critical roles in the absorption, distribution, and elimination of drugs and nutrients. 6 Recently, the US Food and Drug Administration (FDA) released two guidances for drug developers, which include recommendations for conducting in vitro and clinical studies of transporter-mediated DDIs. Further, they provided a list of substrates and/or inhibitors for characterizing interactions mediated by nine membrane transporters: two efflux (P-gp and BCRP) and seven influx (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2). 4 These transporters not only play an important role in the disposition of drugs but also endogenous metabolites, such as creatinine (OCT2, MATE1, and MATE2) and uric acid (OAT1, OAT3, and BCRP). 7 In this study, we conducted extensive in vitro experiments aimed at predicting the potential for 25 small molecule drugs in clinical trials for COVID-19 to cause transporter-mediated DDIs ( Figure 1 ). More specifically, we (1) performed in vitro studies to determine the inhibition potential of the 25 drugs against 11 membrane transporters, and (2) predicted the likelihood for these drugs to cause a clinical transporter-mediated DDI using literature reported plasma concentrations and criteria suggested by the FDA. 4 Finally, using electronic health records (EHRs), we demonstrated that the levels of endogenous compounds that are known substrates of specific transporters are significantly elevated in individuals on the drugs that are predicted inhibitors of the transporters. Overall, these findings suggest that individuals with COVID-19 who may be prescribed these medications are at risk for transporter-mediated DDIs.

The following databases were searched between March 17 and April 1, 2020, to select drugs being evaluated in clinical trials for COVID-19: clinicaltrials.gov, DRUGBANK, and IUPHAR/BPS Guide to Pharmacology. 8 Twenty-five small molecule drugs, which were in clinical trials as of April 1, 2020, were selected for studying transporter-mediated DDIs.

Cell lines used for inhibition studies Transient cells were used for determining the transporter inhibition at one concentration, 100 µM, unless mentioned otherwise. HEK293 Flp-In cells stably overexpressing human OATP2B1, 9 OCT1, 10  OCT2, 11 OAT1, 12 OAT3, 13 MATE1, 14 and MATE2 15 were used for  determining the inhibition potencies, inhibitor activity measurements  to estimate half-maximum inhibitory concentrations (IC 50 ) values, of  selected drugs (see next section). See Supplementary Information for  more information, including methods to establish transient cells expressing OATP1B1, OATP1B3, OATP2B1, OCT1, OCT2, OAT1, OAT3,  MATE1 , and MATE2 in HEK293 Flp-In cells.

Transporter inhibition studies Twenty-five COVID-19 drugs were screened against 11 transporters at a concentration of 100 μM, except for azithromycin (50 µM), baricitinib (50 μM), and tetrandrine (10 μM) due to solubility. The substrate used for each transporter is listed in Table S1 . For OATP1B1, OATP1B3, OATP2B1, OCT1, OCT2, OAT1, OAT3, MATE1, and MATE2, drugs were screened in cells transiently overexpressing each of the transporters. For P-gp and BCRP, membrane vesicles were used and the vesicular transport assays were performed as reported previously 16 with modifications. See Supplementary Information for detailed methods.

The DDI potential for each drug was evaluated in accordance to the 2020 FDA Drug-Drug Interaction Guidance 4 by calculating the ratio of predicted clinically relevant drug concentration (I) to IC 50 (I/IC 50 ). See Supplementary Information for description on the formulas and cutoff values used to predict in vivo DDI potential. Clinical pharmacokinetic characteristics (such as peak plasma concentration (C max ), plasma protein binding percentage, and R b ) were collected from PubMed and FDA-approved labeling (Drugs@FDA ; Table S2 ). If no information was available, fraction unbound ( f u,p ) was determined by Quintara Discovery (Hayward, CA), except for piclidenoson, where the f u,p was not estimated because it was not predicted to result in transporter-mediated inhibition even when assuming f u,p to be 1. R b were estimated to be 0.6 for acidic drug and 1 for all others. The highest possible single dose, and respective C max value, was used for all calculations. If a C max value following the highest possible single dose was not available, the C max was scaled linearly to fit the dose.

Two EHR databases were used to extract information about patient medication use as well as perform real-world data analyses, University of California -San Francisco (UCSF) Research Data Browser and Cerner's Real World COVID-19 Database.

The UCSF Research Data Browser with UCSF patient data from 1982 to September 2020 was utilized to search for patients (both inpatients and outpatients) who had at least one laboratory test value reported for (1) serum/plasma uric acid, (2) triglyceride, (3) LDL cholesterol, (4) total cholesterol, or (5) bilirubin. For each analysis, patients were divided into the "on" or "off " drug group depending on their medication prescriptions for sildenafil, ritonavir, darunavir, and/or lopinavir. See Supplementary Information for detailed methods.

The Cerner COVID-19 database includes EHR data from 62 healthcare facilities across the United States from January 2015 to July 2020 of patients who were in an emergency department or admitted to a hospital for COVID-19. We searched for patients who had (a) at least one positive laboratory test result for SARS-CoV-2, and (b) at least two laboratory test values reported for serum creatinine ( Figure S1 ). Patients were divided into the "on" or "off " drug group depending on their medication prescription(s) for chloroquine (CQ) or hydroxychloroquine (HCQ). See Supplementary Information for detailed methods.

In all analyses comparing patient groups, patients were matched by covariates, including age and sex, using the MatchIt package 17 in R software to be comparable in both groups. 

The Cerner COVID-19 database was also utilized to search for the number of patients who have prescriptions for drugs that are known substrates or inhibitors of the transporters, P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2, OAT1, and OAT3 (Table S8) . See Supplementary Information for detailed methods.

Two-sample two-sided Mann-Whitney U tests with continuity correction were performed to compare "on" and "off " drug groups. Among patients without elevated "Pre" creatinine levels, enrichment of elevated "Post" creatinine levels for those on HCQ or CQ in comparison to the matched control group was calculated by χ 2 test with Yates correction. The ggplot2 was used to plot the data in R software (version 3.4.0).

Among the 25 drugs screened, 15 were antimicrobial agents (10 that inhibit viral replication and 5 that 166 inhibit viral entry) and 10 were anti-inflammatory drugs ( Figure 1 ). Eleven or more compounds reduced transport activity of P-gp, OATP2B1, OATP1B1, OATP1B3, OCT1, MATE1, MATE2, and OAT3 by > 50% (Table S1) . Although there can be differences and variability across different laboratories when reporting inhibition potencies (IC 50 ), our experimentally determined IC 50 values ( Table 1 ) were in agreement (i.e., within 10-fold) with published data (Table S4) .

Substrate-dependent inhibition of OATP1B1 and OATP1B3.

We compared differences in potency of inhibition of various drugs using estradiol 17β-glucuronide (EG) and estrone-3sulfate (ES) or cholecystokinin (CCK) as probe substrates for OATP1B1 and OATP1B3, respectively. In general, inhibition potencies of the drugs tested were lower when [ 3 H]-EG was used as the probe substrate in comparison to [ 3 H]-ES as the probe substrate ( Table 1) , as also reported by Izumi et al. 18 Using the FDA guidance for evaluating transporter-mediated drug interactions, a total of 61 potentially clinically relevant drug-transporter interactions were identified ( Table 2, Table S5 , Figure 2 ). Twenty of the 25 drugs screened were predicted to inhibit at least one of the studied transporters at clinical concentrations. Ritonavir, umifenovir, darunavir, and lopinavir were the most promiscuous clinical inhibitors, with each compound predicted to inhibit at least five transporters at clinically achievable drug levels. In contrast, baricitinib, colchicine, fingolimod, piclidenoson, and prazosin were not predicted to cause any transporter mediated DDIs. Intestinal and hepatic transporters appeared to be more easily inhibited compared with renal transporters, reflecting higher drug concentrations and exposure in the intestines and liver compared with the kidneys. Additionally, intestinal P-gp appeared to be inhibitable by 15 of the 25 drugs predicted to inhibit the transporter at estimated intestinal concentrations ( Figure 2 ).

Since the first whitepaper by the International Transporter Consortium (ITC) was published, 6 many drug labels include information on whether a drug is a substrate or inhibitor of certain transporters. For the drugs in this study that were approved prior to 2010 (n = 14), many clinically relevant transporter interactions were predicted. In particular, 40 interactions were Figure 1 Overall study approach to assess the risks for transporter-mediated drug-drug interactions (DDIs) of 25 drugs in clinical trials to treat patients with coronavirus disease 2019 (COVID-19). (a) Multiple approaches were used in this study, starting with in vitro assays to determine transporter inhibition (1-3), followed by applying predictive methods to evaluate the potential for DDIs (4) (5) , and leveraging real-world data from electronic health records (6) to validate drug-transporter interactions clinically. (b, c) Chemical structures of 25 drugs, which include 10 drugs that inhibit viral replication, 5 drugs that inhibit viral entry, and 10 anti-inflammatory drugs. FDA, US Food and Drug Administration; IC 50 , inhibitor activity measurements to estimate half-maximum inhibitory concentrations. 15 potentially relevant drug-transporter interactions were identified. For example, umifenovir and triazavirin each were predicted to cause 6 and 4 clinically relevant drug-transporter interactions, respectively. Camostat and leflunomide are rapidly converted to their active metabolites, thus the IC 50 for the active metabolites are required for determining the I/IC 50 calculations for hepatic and renal transporters. Although we took a conservative approach, and assumed that the f u,p was 1 for piclidenoson, as the information was not available, the drug was not predicted to cause a DDI for any of the transporters ( Figure 2 , Table 2 , Table S5 ).

To investigate the clinical relevance of the inhibitors identified in vitro, we mined the EHR) database from the UCSF Research Data Browser (n = 2,888,884 total patients from the general population). Specifically, we compared specific laboratory values in patients prescribed commonly used drugs (i.e., sildenafil, darunavir, ritonavir, and lopinavir) to laboratory values in patients not prescribed the respective drug. Endogenous biomarkers chosen and compared for each of these analyses were driven by literaturebased evidence (Table S6) .

To assess whether sildenafil, which was predicted to inhibit BCRP at clinical concentrations, actually inhibited the transporter in patients, we used uric acid levels from the UCSF database as a biomarker of BCRP activity; higher uric acid levels have been previously associated with reduced BCRP activity. Patients prescribed sildenafil had statistically significant higher uric acid levels (average: 6.84 mg/dL vs. 5.94 mg/dL) compared with age-matched and sexmatched controls not prescribed sildenafil (P value < 2.2 × 10 −16 , n = 636 "on" drug, n = 3,180 "off " drug), consistent with inhibition of BCRP ( Figure 3 , Table 3 ). Additional sensitivity analyses, including (1) a maximum separation date of 1 year between the first medication order start date and laboratory collection date, (2) limiting our analysis to patients diagnosed with pulmonary hypertension, and (3) further filtering to only include laboratory values taken on or after initial diagnosis start date, (4) only including sildenafil (i.e., excluding Viagra and Revatio) medication orders with a dose greater than 25 mg in the medication name, and (5) excluding male patients, showed a significant difference between the 2 groups, where patients "on" drug had statistically significant higher uric acid levels compared with patients "off " drug (see P values in Table 3 ). Furthermore, to test the sensitivity of these analyses and selection of controls, multiple iterations were performed for each analysis where the ratio used to sex-match and age-match the two groups was varied; in every iteration, the "on" drug group had significantly higher uric acid levels compared to the "off " drug group (Table S7) .

To assess the potential of ritonavir and darunavir to inhibit OCT1 at clinical concentrations, we used pharmacodynamic end points using data from the UCSF database. That is, reduction in the function of OCT1 has been associated with higher lipid levels. 20 Triglyceride, LDL cholesterol, and total cholesterol levels were significantly increased in patients with HIV prescribed ritonavir compared with age-matched and sex-matched patients with HIV not prescribed ritonavir, when comparing laboratory values taken on or after initial HIV diagnosis start Sildenafil is a predicted clinical inhibitor of BCRP; ritonavir and darunavir are predicted to inhibit OCT1; ritonavir and lopinavir are predicted to inhibit OATP1B1 and OATP1B3.

EHR, electronic health record; LDL, low-density lipoproteins; SUA, serum uric acid.

ARTICLE date, consistent with inhibition of OCT1 ( Figure 3 , Table 3 ). A similar, significant increase was seen in patients with HIV prescribed darunavir ( Table 3) . The percentage of patients with at least one statin prescription was higher in the "on" drug group or comparable between both groups for all ritonavir and darunavir analyses when comparing prescriptions to drugs (classified as antihyperlipidemic-HMG-CoA reductase inhibitors (statins)) with a medication order start date within 1 year before the laboratory collection date (Table S3) .

Patients with HIV prescribed ritonavir and/or lopinavir had significantly higher total bilirubin levels compared to patients with HIV not prescribed ritonavir and/or lopinavir, when comparing laboratory values taken on or after initial HIV diagnosis start date, consistent with inhibition of OATP1B1 and OATP1B3 ( Table 3) .

Serum creatinine levels are determined by glomerular filtration rate and its active transport in renal proximal tubules by transporters, including MATE1. 21 Thus, we used the change in creatinine level over time in patients prescribed HCQ and CQ, which are predicted to inhibit MATE1, to determine whether these drugs may actually inhibit this transporter clinically ( Table 4) . We used the Cerner COVID-19 database (n = 117,496 total patients with COVID-19) to identify patients prescribed HCQ and CQ (Table 4, Figure S1 ). The Cerner database contains data about medication order status (e.g., "complete, " and "incomplete") that informs about medication administration as well as timestamps for laboratory values and medications that provide a temporal relationship between events of interest, and thus used for this analysis instead of the UCSF Research Data Browser.

In the analysis of patients with COVID-19 in the Cerner database who have "pre" creatinine levels within the upper limit of normal range, the "on drug" cohort had a significantly higher prevalence of "post" creatinine levels that were elevated above the normal range than the "off drug" control cohort matched using a propensity score that included age, sex, race, ethnicity, and outcome (death), with a 1:2 ratio (15.41% vs. 11.47%. Chi-square test, P value = 0.024; Table 4 ). As serum creatinine levels can be confounded by underlying kidney disease and by chronic conditions, such as systemic lupus erythematosus, for which long-term therapy with HCQ or CQ can be prescribed, we conducted a sensitivity analysis that excluded those with chronic renal disease and matched patients in the "on drug" and "off drug" cohorts by medication indication for HCQ and CQ. For the patients with COVID-19 with "pre" creatinine levels within the upper limit of normal range and without chronic renal disease, the "on drug" cohort had a significantly higher prevalence of "post" creatinine levels elevated above the normal range than the "off drug" control cohort matched using a propensity score, which included age, sex, race, ethnicity, outcome (death), and medication indication (systemic lupus erythematosus, discoid lupus, and rheumatoid arthritis, and malaria), with a 1:2 ratio (14.23% vs. 8.37%. Chisquare test, P value = 4.6 × 10 -4 , Table 4 , Table S3 ). Creatinine elevations are consistent with inhibition of MATEs.

In the present study, we determined the inhibition of 25 drugs (18 approved drugs, 6 investigational drugs, and 1 recently approved) in COVID-19 clinical trials against 11 transporters and evaluated their potential to cause transporter-mediated DDIs. Patients with COVID-19 are often older and are taking multiple medications, many of which are substrates of transporters and thus, subject to transporter-mediated DDI. For example, furosemide (OAT1 and OAT3 substrate), atorvastatin (OATP1B1 and OATP1B3 substrate), and morphine (OCT1 substrate) are known substrates of transporters and are commonly used in patients with COVID-19 to treat co-existing conditions (Table S8) .

This study resulted in three major findings. First, many of the drugs tested, which are in clinical trials for COVID-19, inhibited transporters in cellular assays with certain transporters being sensitive to inhibition by multiple drugs. Second, most of the drugs (20 of 25) were predicted to cause at least one clinical DDI; that is, the concentrations of these drugs that inhibited the transporters in cellular assays were equal to or greater than drug levels known to result in clinical DDIs. Finally, real-world data from the EHR were consistent with our predictions of transporter-mediated DDIs. In particular, recorded levels of certain solutes (such as creatinine and uric acid), which are endogenous substrates of particular transporters, were significantly elevated in individuals taking drugs predicted to inhibit the transporters clinically, in comparison to matched subjects not taking the drugs ( Table 3, Table 4 ). Below we discuss each of these findings. In the main analysis, patients were matched by age, sex, race, ethnicity, and outcome (mortality). In analysis 1, patients with chronic kidney disease were excluded and patients were matched by asge, sex, race, ethnicity, outcome (mortality), and medication indication. Chi-squared tests were performed to compare the percent of patients who have creatinine levels within the upper limit of normal range in the "on" drug group and the control ("off") drug group. CQ, chloroquine; EHR, electronic health record; HCQ, hydroxychloroquine. Woman's normal creatinine levels = 1.1 mg/dL; Man's normal creatinine levels = 1.2 mg/dL

Seventeen of the 25 drugs tested in this study have been reported to be substrates or inhibitors of 1 or more of the 11 membrane transporters that are targets for DDIs (Table S1) ; however, none of them have been assessed against all 11 transporters in a single study. There were 8 drugs where no information was available about their interactions with any of the 11 transporters, including: (1) 3 drugs (HCQ, ribavirin, and thalidomide), which were approved before 2000 and have no information about transporter inhibition reported in their FDA approved labels, their product inserts, or the literature; (2) 2 drugs (fingolimod and ruxolitinib), which were approved after 2010 but have limited information about their IC 50 values in their labels and product inserts; and (3) 3 drugs (piclidenoson, triazavirin, and umifenovir), which have not been approved. Examination of the data suggest that hepatic uptake transporters, including OATP1B1, OATP1B3, and OCT1, are subject to inhibition by multiple drugs in clinical trials for COVID-19. These hepatic transporters are known to interact with structurally diverse molecules from a range of pharmacologic classes and play critical roles in xenobiotic detoxification. 22, 23 OATP2B1, also in the liver and intestines, similarly interacts with multiple drugs. In the kidneys, MATE1 and MATE2 were inhibited by several drugs (Figure 2 , Table 2 ). These transporters are known to interact with many drugs, 24 and clinically relevant DDIs have been reported between inhibitors of MATE1, such as cimetidine and the commonly prescribed antidiabetic drug, metformin. 25 In contrast, the renal transporters OCT2 and OAT1 and the intestinal efflux transporter BCRP, were not subject to inhibition by multiple drugs ( Table 1 , Figure 2 ). The majority of the drugs on the market that inhibit OCT2 are more potent inhibitors of MATE1 and MATE2 at clinically relevant concentrations, such as pyrimethamine and trimethoprim. 26 OAT1, which is responsible for the renal secretion of many acidic drugs, such as tenofovir, is inhibited by a few prescription drugs, such as probenecid, but is considered a less promiscuous paralog than OAT3, which interacts with a more diverse array of drugs and their metabolites. 13 The fact that BCRP was not inhibited by most of the drugs tested ( Table 1 ) is interesting. BCRP has an endogenous role in the elimination of uric acid (Table S6) , and drugs that inhibit this transporter may increase risk for hyperuricemia and gout; whereas drugs that inhibit other uric acid transporters, such as URAT1, may decrease uric acid levels.

Most of the drugs (20 of 25) tested were predicted to cause at least one transporter-mediated clinical DDI

A surprising finding of our study was that many of the drugs in clinical trials for COVID-19 had the potential to cause at least one transporter-mediated DDI. In particular, 20 of the 25 drugs screened were predicted to inhibit at least 1 of the 11 transporters at clinically achievable concentrations ( Table 2 ). Ten of the 20 drugs have supporting information in the literature suggesting that they cause DDIs in humans or mice or have reported adverse events that are consistent with transporter inhibition ( Table S6 ). The finding that the drugs may cause DDIs mediated by one or more transporters is consistent with the notion that these transporters work together with drug metabolizing enzymes to detoxify a plethora of xenobiotics, including environmental toxins, and exogenous chemical and prescription drugs. Thus, the transporters and enzymes interact with structurally diverse molecules and are subject to inhibition interactions. For example, azithromycin, a known in vivo P-gp inhibitor, increases plasma levels of the non-sedating antihistamine, fexofenadine, and the anticoagulant, ximelagatran, both of which are substrates of P-gp. 27, 28 The antiviral combination drugs, lopinavir/ritonavir or lopinavir/darunavir, are known in vivo inhibitors of OATP1B1, OATP1B3, and P-gp. As such, they are associated with increase plasma levels of rosuvastatin, which is a substrate of OATP1B1/B3 and BCRP, 29, 30 and fexofenadine, which is a P-gp substrate. 31 The effectiveness and cardiac safety of HCQ, CQ, and azithromycin in patients with COVID-19 have been the subject of considerable discussion in the literature. [32] [33] [34] [35] One of the major adverse events of these drugs is prolongation of the QT interval. This study and others have shown that azithromycin, HCQ, and CQ are substrates and inhibitors of P-gp. 27, 28, 36, 37 Therefore, the use of azithromycin in combination with CQ or HCQ needs to be carefully assessed and monitored.

Real-world data from the EHR were consistent with our predictions of transporter-mediated DDIs

Human genetic association studies and knockout mouse studies have shown that reduced function genetic variants of BCRP, OAT1, and OAT3 are associated with higher uric acid levels. 12, 38, 39 Similarly, genetic variants in OCT2 and MATE1 are associated with higher serum creatine levels and, hence, reduced estimated glomerular filtration rate. [40] [41] [42] Finally, genetic variants of OATP1B1 and OATP1B3 are associated with increased bilirubin levels. 43 All of these metabolites are also substrates of the respective transporters. Additionally, reduced function polymorphisms in OCT1 and Oct1 knockout mice have been shown to have increased plasma levels of LDL cholesterol, total cholesterol, and triglycerides. 20 Because levels of uric acid, creatinine, bilirubin, and various lipids are routinely measured and recorded in the EHR, these levels may be exploited to validate predictions from in vitro transporter assays of clinically relevant DDIs. Sildenafil has been shown to increase risk of gout (Table S6 ), and we found that patients who were prescribed sildenafil, a potent inhibitor of BCRP, had significantly elevated serum uric acid levels relative to patients not prescribed sildenafil (Table 3, Figure 3 ). In our study, average serum uric acid levels in the "on" drug group ranged from 6.8-7.4 mg/dL whereas the average levels for the "off " drug group ranged from 5.0-6.3 mg/dL, across all analyses. Previous studies have reported incidents of sildenafil-induced gouty arthritis. 44, 45 In contrast, other inhibitors of phosphodiesterase 5, such as vardenafil and tadalafil, are weak inhibitors of BCRP 46 and serum uric acid levels have been shown to significantly decrease following a 1 year treatment with vardenafil. 47 In addition to exploiting uric acid as an endogenous substrate of BCRP, we used lipid levels as biomarkers of OCT1 activity. That is, patients prescribed ritonavir and/or darunavir, both of which are OCT1 inhibitors ( Table 1, Table 2 ), had significantly higher triglyceride, LDL cholesterol, and total cholesterol levels, compared with patients not prescribed either of these drugs (Table 3, Figure 3 ). Increases in cholesterol and triglyceride levels are listed as possible side effects in the FDA product label for ritonavir, as well as the Warnings and Precautions section to ensure these levels are monitored before and during therapy. 48 Although other targets of ritonavir that affect liver metabolism may account for the observed increases in lipid levels associated with these drugs, reduced OCT1 activity is consistent with the elevated lipid levels. 20 The in vitro studies and in vivo DDI risk predictions were focused on 25 drugs, selected during the beginning of the COVID-19 shelter-in-place; therefore, other drugs which may be currently used, such as dexamethasone, were not included here. However, based on transporter inhibition studies in the literature (Table S9) , it is unlikely that dexamethasone will reach the FDA criteria to cause a transporter-mediated DDI (< 0.2 µM; Table S9 ). A limitation of transporter inhibition assays is nonspecific binding of compounds to cell-culture plates and/or cells during pre-incubation. 49 However, the pre-incubation step was not performed in our assays except for OATP1B1 and OATP1B3, which is recommended in the FDA guidance. 4 The EHR analyses were limited by lack of data on how long patients were on each respective medication, patient compliance (i.e., picking up medication from pharmacy, and abiding by dosing schedule), and robust controls (i.e., other phosphodiesterase 5 and protease inhibitors), as well as difficulty in getting measurable outcomes and noisy data. As more EHR data become available for research purposes, we will be able to account for these variables and covariates as well as increase the sample size and robustness of our analysis. Importantly, the endogenous solutes and lipids measured may be elevated for other reasons beyond transporter inhibition (e.g., creatinine elevation can result from dehydration and elevation of lipids, in particular triglycerides, can be detected for hours after high-fat meals); thus, the EHR results need to be interpreted cautiously and only as supporting information. Additional studies, such as controlled randomized clinical trials of DDIs or use of validated biomarkers for transporter-mediated DDIs, need to be conducted. 7, 50 CONCLUSION This study highlights that drugs for COVID-19 have the potential to cause transporter-mediated DDIs. Our study suggests that patients with COVID-19, who are often older and on various concomitant medications, should be carefully monitored for known adverse drug reactions. However, clinical DDI studies in healthy volunteers or patients are needed to confirm these DDI predictions.

Supplementary information accompanies this paper on the Clinical Pharmacology & Therapeutics website (www.cpt-journal.com).

The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register

A study of potential adverse drug-drug interactions among prescribed drugs in medicine outpatient department of a tertiary care teaching hospital

A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates

FDA drugdrug interaction guidance -comparison analysis and action plan by pharmaceutical industrial scientists

An overview of prevalence, determinants and health outcomes of polypharmacy

Membrane transporters in drug development

Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the international transporter consortium

A rational roadmap for SARS-CoV-2/ COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29

Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives

Discovery of competitive and noncompetitive ligands of the organic cation transporter 1 (OCT1; SLC22A1)

Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2

Molecular mechanisms for species differences in organic anion transporter 1, OAT1: implications for renal drug toxicity

Drug metabolites potently inhibit renal organic anion transporters, OAT1 and OAT3

Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling

The effect of nizatidine, a MATE2K selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin in healthy volunteers

Interactions of oral molecular excipients with breast cancer resistance protein

MatchIt nonparametric preprocessing for parametric causal inference

Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17β-glucuronide, estrone-3-sulfate, and sulfobromophthalein

Prediction of transporter-mediated drug-drug interactions for baricitinib

Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content

The complexities of interpreting reversible elevated serum creatinine levels in drug development: does a correlation with inhibition of renal transporters exist?

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

Organic cation transporters in health and disease

Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics

Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney

Estimation of changes in serum creatinine and creatinine clearance caused by renal transporter inhibition in healthy subjects

Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study

Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers

Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers

Steadystate pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin

Time-dependent interaction between lopinavir/ritonavir and fexofenadine

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment

Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization Pharmacovigilance database

Considerations for drug interactions on QTc in exploratory COVID-19 treatment

Interaction of hydroxychloroquine with pharmacokinetically important drug transporters

Intracellular ABCB1 as a possible mechanism to explain the synergistic effect of hydroxychloroquineazithromycin combination in COVID-19 therapy

Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ ABCG2

Decreased extra-renal urate excretion is a common cause of hyperuricemia

Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function

Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases

Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies

Genome-wide association meta-analysis for total serum bilirubin levels

Gouty arthritis at interphalangeal joint of foot after sildenafil use: a case report

Acute gouty arthritis after taking sildenafil: an old disease with a new etiology

The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter

Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study

A systematic in vitro investigation of the inhibitor preincubation effect on multiple classes of clinically relevant transporters

Drugdrug interactions involving renal OCT2/MATE transporters: clinical risk assessment may require endogenous biomarker-informed approach

The authors would like to acknowledge (i) members of the Sirota Lab for useful discussion and Dr. Boris Oskotsky for technical support; (ii) Quintara Discovery (QDI) (Hayward, CA) for their service to determine protein binding for tetrandrine and triazavirin; and (iii) the Cerner Clinical Research Team, for providing access to the Cerner COVID-19 de-identified data environment and for technical assistance. 

The authors declared no competing interests for this work. 

As Deputy Editor-in-Chief of Clinical Pharmacology and Therapeutics, Kathleen M. Giacomini was not involved in the review or decision process for this paper.